Showing results (11-20 of 22) with videos related to

Sort By:
Pageof 3
Techniques in Coloproctology|October 13, 2018
Correction to: Long-term results after stapled hemorrhoidopexy: a survey study with mean follow-up of 12 yearsA Sturiale, B Fabiani, C Menconi, et al.
Techniques in Coloproctology|October 6, 2018
Long-term results after stapled hemorrhoidopexy: a survey study with mean follow-up of 12 yearsA Sturiale, B Fabiani, C Menconi, et al.
Techniques in Coloproctology|January 10, 2018
Effectiveness of sacral nerve stimulation in fecal incontinence after multimodal oncologic treatment for pelvic malignancies: a multicenter study with 2-year follow-upM Schiano di Visconte, G A Santoro, N Cracco, et al.
Leukemia|October 17, 2003
Stimulation of non-Hodgkin's lymphoma via HVEM: an alternate and safe way to increase Fas-induced apoptosis and improve tumor immunogenicityR T Costello, F Mallet, B Barbarat, et al.
La Revue De Medecine Interne|March 25, 2008
[Chronic lymphocytic leukaemia: current management]T Aurran-Schleinitz, C Arnoulet, V Ivanov, et al.
Journal of Endocrinological Investigation|July 11, 2012
Beyond waist circumference in an adult male population of Southern Italy: Is there any role for subscapular skinfold thickness in the relationship between insulin-like growth factor-I system and metabolic parameters?S Savastano, A Barbato, C Di Somma, et al.
Gynecologic Oncology|September 1, 1990
Chemical enhancement of cisplatin cytotoxicity in a human ovarian and cervical cancer cell lineG M Boike, E Petru, B U Sevin, et al.
Journal of Medicinal Chemistry|January 6, 1999
Homocamptothecins: synthesis and antitumor activity of novel E-ring-modified camptothecin analoguesO Lavergne, L Lesueur-Ginot, F Pla Rodas, et al.
Journal of Immunology (Baltimore, Md. : 1950)|October 18, 2000
Reciprocal expression of the TNF family receptor herpes virus entry mediator and its ligand LIGHT on activated T cells: LIGHT down-regulates its own receptorY Morel, J M Schiano de Colella, J Harrop, et al.
Bone Marrow Transplantation|June 14, 2006
A phase II trial of rituximab as adjuvant to intensive sequential chemotherapy in patients under 60 years with untreated poor-prognosis diffuse large B-cell lymphomaD Coso, C Sebban, O Boulat, et al.
Pageof 3